LMAT LeMaitre Vascular Inc

$87.49

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending
Expected on
Report Time: Unknown Release Time
The Whisper Number
Consensus Estimate:
Revenue Estimate:

Latest Earnings Insight

Updated On 10/6/2025

About LeMaitre Vascular Inc

LeMaitre Vascular, Inc. designs, markets, sells, services and supports medical devices and implants for the treatment of peripheral vascular diseases worldwide. The company is headquartered in Burlington, Massachusetts.

Website: https://www.lemaitre.com

Sector
LIFE SCIENCES
Industry
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
1158895
Address
63 SECOND AVENUE, BURLINGTON, MA, US
Valuation
Market Cap
$1.95B
P/E Ratio
44.70
PEG Ratio
2.27
Price to Book
5.77
Performance
EPS
$1.93
Dividend Yield
0.93%
Profit Margin
20.00%
ROE
13.90%
Technicals
50D MA
$88.78
200D MA
$91.40
52W High
$109.31
52W Low
$61.90
Fundamentals
Shares Outstanding
23M
Target Price
$105.62
Beta
0.88

LMAT EPS Estimates vs Actual

Estimated
Actual

LMAT News & Sentiment

Aug 28, 2025 • GlobeNewswire NEUTRAL
LeMaitre to Participate at Upcoming Investor Conferences in September
BURLINGTON, Mass., Aug. 28, 2025 ( GLOBE NEWSWIRE ) -- LeMaitre Vascular, Inc. ( Nasdaq:LMAT ) announced today that management will participate in four upcoming investor conferences.
Aug 27, 2025 • Zacks Commentary BULLISH
Is LeMaitre ( LMAT ) a Solid Growth Stock? 3 Reasons to Think "Yes"
LeMaitre (LMAT) possesses solid growth attributes, which could help it handily outperform the market.
Aug 25, 2025 • Zacks Commentary NEUTRAL
NVNO's Shares Decline on Unfavorable FDA Review Outcome for VenoValve
enVVeno Medical shares plunge after the FDA rejects its VenoValve PMA, citing insufficient trial data and safety concerns tied to the surgical procedure.
Aug 22, 2025 • Zacks Commentary NEUTRAL
NVCR Stock Slips Despite PMA Application to Treat Pancreatic Cancer
NovoCure submits a PMA to the FDA for TTFields therapy in pancreatic cancer, aiming to expand its oncology reach.
Aug 11, 2025 • Zacks Commentary BULLISH
LeMaitre ( LMAT ) is an Incredible Growth Stock: 3 Reasons Why
LeMaitre (LMAT) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Aug 06, 2025 • Motley Fool SOMEWHAT-BULLISH
LeMaitre ( LMAT ) Q2 Revenue Jumps 15%
LeMaitre Vascular ( NASDAQ:LMAT ) , a medical device company focused on vascular surgeons, reported its latest quarterly earnings after the bell on August 5, 2025. The company delivered GAAP results ahead of expectations, posting GAAP earnings per share of $0.60, above the anticipated $0.57 ( ...
Sentiment Snapshot

Average Sentiment Score:

0.124
50 articles with scored sentiment

Overall Sentiment:

Neutral

LMAT Reported Earnings

Apr 30, 2025
Mar 31, 2025 (Pre market)
0.0 Surprise
  • Reported EPS: $0.00
  • Estimate: $0.00
  • Whisper:
  • Surprise %: 0.0%
Feb 25, 2025
Dec 31, 2024 (Post market)
0.0 Surprise
  • Reported EPS: $0.49
  • Estimate: $0.49
  • Whisper:
  • Surprise %: 0.0%
Oct 31, 2024
Sep 30, 2024 (Post market)
0.05 Surprise
  • Reported EPS: $0.49
  • Estimate: $0.44
  • Whisper:
  • Surprise %: 11.4%
Aug 01, 2024
Jun 30, 2024 (Post market)
0.05 Surprise
  • Reported EPS: $0.52
  • Estimate: $0.47
  • Whisper:
  • Surprise %: 10.6%
May 02, 2024
Mar 31, 2024 (Post market)
0.05 Surprise
  • Reported EPS: $0.44
  • Estimate: $0.39
  • Whisper:
  • Surprise %: 12.8%
Feb 27, 2024
Dec 31, 2023 (Post market)
0.02 Surprise
  • Reported EPS: $0.38
  • Estimate: $0.36
  • Whisper:
  • Surprise %: 5.6%
Nov 01, 2023
Sep 30, 2023 (Post market)
0.03 Surprise
  • Reported EPS: $0.33
  • Estimate: $0.30
  • Whisper:
  • Surprise %: 10.0%
Aug 01, 2023
Jun 30, 2023 (Post market)
0.04 Surprise
  • Reported EPS: $0.36
  • Estimate: $0.32
  • Whisper:
  • Surprise %: 12.5%
May 02, 2023
Mar 31, 2023 (Post market)
0.02 Surprise
  • Reported EPS: $0.27
  • Estimate: $0.25
  • Whisper:
  • Surprise %: 8.0%

Financials